Report Overview
The Liver Cancer Diagnostics Market is set to reach USD 11.85billion in 2035, growing at a CAGR of 9.8 % from USD 5.11 billion in 2026.
Highlights:
- 1Rising liver cancer incidence is driving increasing adoption of biomarker testing, molecular diagnostics, and advanced imaging technologies.
- 2Alpha-fetoprotein (AFP) remains the most widely used biomarker, while multi-biomarker panels and liquid biopsy technologies are gaining clinical importance.
- 3Molecular diagnostics and next-generation sequencing are expanding rapidly due to precision oncology and companion diagnostic applications.
- 4North America currently leads the market, while Asia-Pacific is expected to experience the fastest growth because of the high burden of liver cancer.
The increasing global incidence of liver cancer driven by chronic hepatitis B and C infections, non-alcoholic fatty liver disease (NAFLD), cirrhosis, alcohol-related liver disease, and metabolic disorders continues to accelerate demand for advanced diagnostic solutions. Technological advances in liquid biopsy, next-generation sequencing (NGS), artificial intelligence-assisted imaging, multiplex biomarker assays, and precision oncology are improving diagnostic accuracy and enabling earlier disease detection. Growing implementation of cancer screening programs and personalized medicine is expected to support sustained market growth through 2035.
Market Drivers
Increasing prevalence of hepatocellular carcinoma and chronic liver diseases.
Rising hepatitis B and hepatitis C infections globally.
Growing adoption of precision oncology and companion diagnostics.
Expansion of cancer screening and surveillance programs.
Technological advancements in molecular diagnostics and liquid biopsy.
Market Restraints
High costs associated with advanced molecular diagnostic testing.
Limited access to specialized diagnostics in low-income regions.
Stringent regulatory approval requirements.
Variability in biomarker sensitivity and specificity.
Reimbursement limitations for emerging diagnostic technologies.
Market Opportunities
Expansion of liquid biopsy-based liver cancer diagnostics.
Development of novel biomarker panels.
Growing adoption of artificial intelligence-assisted imaging.
Increasing use of companion diagnostics in targeted therapies
Disease & Epidemiology Analysis
Liver cancer remains one of the leading causes of cancer-related mortality worldwide, with hepatocellular carcinoma accounting for the majority of diagnosed cases. The growing prevalence of chronic hepatitis B virus (HBV), hepatitis C virus (HCV), cirrhosis, metabolic dysfunction-associated steatotic liver disease (MASLD), obesity, diabetes, and alcohol-related liver disease continues to increase the global disease burden. Rising implementation of surveillance programs among high-risk populations is significantly increasing demand for sensitive imaging modalities, biomarker testing, and molecular diagnostic technologies that facilitate earlier diagnosis and improved clinical outcomes.
Government Regulatory Landscape Table
Region/Country | Regulatory Authority | Regulatory Focus |
United States | U.S. Food and Drug Administration (FDA) | Regulates liver cancer diagnostic assays, companion diagnostics, molecular tests, imaging software, and biomarker-based diagnostics through analytical validation, clinical performance, QSR, and post-market surveillance. |
European Union | European Commission (IVDR) & National Competent Authorities | Oversees performance evaluation, conformity assessment, quality management systems, companion diagnostics, and post-market monitoring under IVDR. |
Japan | Pharmaceuticals and Medical Devices Agency (PMDA) & Ministry of Health, Labour and Welfare (MHLW) | Regulates oncology diagnostic technologies through clinical evaluation, manufacturing quality, safety assessment, and regulatory approval. |
China | National Medical Products Administration (NMPA) | Governs registration, clinical validation, manufacturing quality, biomarker testing, and commercialization of liver cancer diagnostics. |
Market Segmentation
By Diagnostic Modality
Imaging diagnostics continue to dominate the market as ultrasound, CT, and MRI remain the primary tools for liver lesion detection and disease staging. Laboratory diagnostics and histopathology remain essential for diagnosis confirmation, while molecular diagnostics are experiencing the fastest growth due to increasing adoption of genomic profiling, liquid biopsy, and precision oncology.
By Technology
Immunohistochemistry remains widely utilized for tumor characterization and pathology evaluation. PCR-based testing continues supporting biomarker detection and viral diagnostics, while next-generation sequencing is the fastest-growing technology owing to increasing use in precision oncology and targeted therapy selection. FISH and immunoassays continue supporting specialized biomarker evaluation and companion diagnostic applications.
By Biomarker
Alpha-fetoprotein (AFP) remains the most widely utilized biomarker for liver cancer screening and monitoring. AFP-L3 and des-gamma-carboxy prothrombin (DCP/PIVKA-II) are increasingly adopted to improve diagnostic sensitivity and specificity. Glypican-3 and emerging multi-biomarker panels continue gaining clinical importance for early diagnosis and precision oncology.
Regional Analysis
North America
North America dominates the liver cancer diagnostics market due to advanced oncology infrastructure, widespread adoption of molecular diagnostics, favorable reimbursement policies, and significant investment in precision medicine.
Europe
Europe maintains a strong market position through established cancer screening programs, advanced pathology laboratories, and increasing adoption of companion diagnostics and next-generation sequencing.
Asia-Pacific
Asia-Pacific is expected to register the fastest market growth due to the high prevalence of hepatitis B infection, increasing liver cancer incidence, expanding healthcare infrastructure, and growing investment in oncology diagnostics.
South America
South America is witnessing steady market expansion driven by improving cancer diagnosis capabilities, increasing healthcare investments, and broader access to advanced diagnostic technologies.
Middle East & Africa
The Middle East & Africa market continues growing through healthcare modernization initiatives, improving cancer care infrastructure, and increasing awareness regarding early cancer diagnosis.
Rest of the World
The Rest of the World is experiencing gradual growth supported by expanding oncology services, improving diagnostic laboratory capacity, and increasing implementation of cancer screening initiatives.
Regulatory Landscape
Liver cancer diagnostic products are regulated by authorities including the U.S. Food and Drug Administration (FDA), the European Commission under the In Vitro Diagnostic Regulation (IVDR), Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and China's National Medical Products Administration (NMPA). Regulatory agencies require comprehensive analytical validation, clinical performance studies, biomarker verification, manufacturing quality compliance, and post-market surveillance before commercialization. Increasing regulatory attention is focused on companion diagnostics, next-generation sequencing assays, liquid biopsy technologies, artificial intelligence-enabled diagnostic software, and multi-biomarker testing platforms that support precision oncology.
Pipeline Analysis
The liver cancer diagnostics pipeline is rapidly evolving through development of liquid biopsy technologies, circulating tumor DNA (ctDNA) assays, circulating tumor cell (CTC) detection, next-generation sequencing panels, multiplex biomarker assays, artificial intelligence-assisted imaging, radiomics, proteomics, metabolomics, and companion diagnostics supporting targeted therapies. Manufacturers and research organizations are investing heavily in highly sensitive non-invasive diagnostic platforms capable of improving early detection, treatment selection, disease monitoring, and recurrence surveillance.
Reimbursement Landscape
Reimbursement for liver cancer diagnostics is well established for conventional imaging, pathology, and laboratory testing across most developed healthcare systems. North America provides reimbursement for medically necessary biomarker testing, molecular diagnostics, companion diagnostics, and next-generation sequencing through Medicare, Medicaid, and private insurers, subject to clinical evidence and coverage policies. European countries reimburse liver cancer diagnostic procedures through national healthcare systems, while reimbursement for advanced genomic profiling and liquid biopsy continues expanding as clinical utility becomes increasingly validated. Emerging markets are gradually strengthening reimbursement through national cancer control programs and oncology care initiatives.
Competitive Landscape
F. Hoffmann-La Roche Ltd.
Roche develops comprehensive liver cancer diagnostic solutions including molecular diagnostics, tissue diagnostics, companion diagnostics, and immunohistochemistry platforms supporting precision oncology.
Abbott Laboratories
Abbott provides immunoassays, clinical chemistry platforms, molecular diagnostics, and biomarker testing solutions supporting liver disease and oncology diagnostics.
Siemens Healthineers AG
Siemens Healthineers offers advanced imaging systems, laboratory diagnostics, immunoassays, and digital healthcare technologies supporting liver cancer diagnosis.
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific develops molecular diagnostic assays, PCR technologies, sequencing solutions, and precision oncology products supporting liver cancer diagnostics.
Danaher Corporation
Danaher provides molecular diagnostics, genomics technologies, life science solutions, and laboratory automation supporting oncology biomarker testing.
Agilent Technologies, Inc.
Agilent specializes in pathology solutions, immunohistochemistry assays, companion diagnostics, and genomic technologies supporting liver cancer diagnosis.
QIAGEN N.V.
QIAGEN develops molecular diagnostic assays, sample preparation technologies, PCR kits, and companion diagnostics supporting precision oncology.
bioMérieux
bioMérieux provides molecular diagnostic technologies, infectious disease testing, and biomarker solutions supporting oncology laboratory workflows.
Bio-Rad Laboratories, Inc.
Bio-Rad develops molecular testing systems, digital PCR technologies, immunoassays, and quality control products supporting cancer diagnostics.
Illumina, Inc.
Illumina is a global leader in next-generation sequencing platforms enabling genomic profiling, biomarker discovery, and precision oncology applications for liver cancer.
Key Developments
January 2026: Guardant Health expanded its liquid biopsy portfolio with advanced multi-cancer genomic testing capabilities.
November 2025: Roche introduced enhanced companion diagnostic solutions supporting precision oncology for liver cancer.
October 2025: Illumina expanded oncology sequencing applications for comprehensive tumor genomic profiling.
September 2025: Thermo Fisher Scientific launched updated next-generation sequencing workflows for solid tumor diagnostics.
August 2025: Agilent Technologies expanded immunohistochemistry assay offerings supporting liver cancer pathology.
Strategic Insights and Future Market Outlook
The global liver cancer diagnostics market is expected to experience robust growth through 2035 as healthcare systems increasingly prioritize early cancer detection, precision medicine, and personalized treatment strategies. Continuous innovation in liquid biopsy, multi-biomarker testing, next-generation sequencing, artificial intelligence-assisted imaging, and companion diagnostics will significantly improve diagnostic accuracy and clinical decision-making. Strategic collaborations among diagnostic manufacturers, pharmaceutical companies, research institutions, and healthcare providers will accelerate development of novel biomarker-driven diagnostic solutions. As screening programs expand and precision oncology becomes increasingly integrated into routine cancer care, liver cancer diagnostics will remain a rapidly evolving segment of the global oncology diagnostics market.
Liver Cancer Diagnostics Market Scope:
| Report Metric | Details |
|---|---|
| Total Market Size in 2026 | USD 5.11 billion |
| Total Market Size in 2035 | USD 11.85billion |
| Forecast Unit | USD Billion |
| Growth Rate | 9.8 % |
| Study Period | 2021 to 2035 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2035 |
| Segmentation | Diagnostic Modality, Technology, End User, Geography |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|
Market Segmentation
Diagnostic Modality
Technology
End User
Geography
Geographical Segmentation
North America, South America, Europe, Middle East and Africa, Asia Pacific
Table of Contents
1. EXECUTIVE SUMMARY
1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations
2. RESEARCH METHODOLOGY
2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations
3. GLOBAL LIVER CANCER DIAGNOSTICS MARKET OVERVIEW, SIZE & FORECAST
3.1 Market Definition & Scope
3.2 Disease Overview
3.3 Disease Evolution and Diagnostic Landscape
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021–2025)
3.6 Market Forecast (2026–2035)
3.7 Disease Prevalence Analysis
3.8 Diagnosed Patient Population Analysis
3.9 Liver Cancer Diagnostic Testing Volume Analysis
3.10 Patient Diagnostic Pathway Analysis
4. MARKET DYNAMICS
4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges
5. INDUSTRY LANDSCAPE
5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape
6. INNOVATION LANDSCAPE
6.1 Emerging Technologies
6.2 Product Innovation
6.3 Liquid Biopsy for Liver Cancer
6.4 Artificial Intelligence in Liver Cancer Diagnostics
6.5 Companion Diagnostics Development
6.6 Biomarker Discovery
6.7 Technology Roadmap
7. REGULATORY LANDSCAPE
7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements
8. GLOBAL LIVER CANCER DIAGNOSTICS MARKET LANDSCAPE ANALYSIS
8.1 Analysis by Diagnostic Modality
8.1.1 Imaging Diagnostics
8.1.2 Laboratory Diagnostics
8.1.3 Histopathology
8.1.4 Molecular Diagnostics
8.2 Analysis by Technology
8.2.1 Immunohistochemistry (IHC)
8.2.2 Polymerase Chain Reaction (PCR)
8.2.3 Next-Generation Sequencing (NGS)
8.2.4 Fluorescence In Situ Hybridization (FISH)
8.2.5 Immunoassays
8.3 Analysis by Biomarker
8.3.1 Alpha-Fetoprotein (AFP)
8.3.2 AFP-L3
8.3.3 Des-Gamma-Carboxy Prothrombin (DCP/PIVKA-II)
8.3.4 Glypican-3 (GPC3)
8.3.5 Other Biomarkers
8.4 Analysis by Clinical Application
8.4.1 Screening & Surveillance
8.4.2 Early Detection
8.4.3 Diagnosis
8.4.4 Treatment Selection
8.4.5 Disease Monitoring
9. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SEGMENT ANALYSIS (2021–2035)
9.1 By Product
9.1.1 Instruments
9.1.2 Reagents & Consumables
9.1.3 Software
9.2 By Technology
9.2.1 Immunohistochemistry (IHC)
9.2.2 Polymerase Chain Reaction (PCR)
9.2.3 Next-Generation Sequencing (NGS)
9.2.4 Fluorescence In Situ Hybridization (FISH)
9.2.5 Immunoassays
9.2.6 Other Technologies
9.3 By End User
9.3.1 Hospitals
9.3.2 Diagnostic Laboratories
9.3.3 Academic & Research Institutes
9.3.4 Cancer Research Centers
10. GLOBAL LIVER CANCER DIAGNOSTICS MARKET GEOGRAPHICAL ANALYSIS (2021–2035)
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa
11. GLOBAL LIVER CANCER DIAGNOSTICS MARKET COUNTRY ANALYSIS (2021–2035)
11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Japan
11.9 China
11.10 South Korea
11.11 India
11.12 Australia
11.13 Brazil
11.14 Mexico
11.15 Saudi Arabia
11.16 South Africa
12. COMPETITIVE LANDSCAPE
12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches
13. COMPANY PROFILES
13.1 F. Hoffmann-La Roche Ltd.
13.1.1 Company Overview
13.1.2 Financials
13.1.3 Product Portfolio
13.1.4 Recent Developments
13.2 Abbott Laboratories
13.2.1 Company Overview
13.2.2 Financials
13.2.3 Product Portfolio
13.2.4 Recent Developments
13.3 Siemens Healthineers AG
13.3.1 Company Overview
13.3.2 Financials
13.3.3 Product Portfolio
13.3.4 Recent Developments
13.4 Thermo Fisher Scientific Inc.
13.4.1 Company Overview
13.4.2 Financials
13.4.3 Product Portfolio
13.4.4 Recent Developments
13.5 Danaher Corporation
13.5.1 Company Overview
13.5.2 Financials
13.5.3 Product Portfolio
13.5.4 Recent Developments
13.6 Agilent Technologies, Inc.
13.6.1 Company Overview
13.6.2 Financials
13.6.3 Product Portfolio
13.6.4 Recent Developments
13.7 QIAGEN N.V.
13.7.1 Company Overview
13.7.2 Financials
13.7.3 Product Portfolio
13.7.4 Recent Developments
13.8 bioMérieux
13.8.1 Company Overview
13.8.2 Financials
13.8.3 Product Portfolio
13.8.4 Recent Developments
13.9 Bio-Rad Laboratories, Inc.
13.9.1 Company Overview
13.9.2 Financials
13.9.3 Product Portfolio
13.9.4 Recent Developments
13.10 Illumina, Inc.
13.10.1 Company Overview
13.10.2 Financials
13.10.3 Product Portfolio
13.10.4 Recent Developments
13.11 Guardant Health, Inc.
13.11.1 Company Overview
13.11.2 Financials
13.11.3 Product Portfolio
13.11.4 Recent Developments
13.12 Exact Sciences Corporation
13.12.1 Company Overview
13.12.2 Financials
13.12.3 Product Portfolio
13.12.4 Recent Developments
13.13 Sysmex Corporation
13.13.1 Company Overview
13.13.2 Financials
13.13.3 Product Portfolio
13.13.4 Recent Developments
13.14 Fujifilm Holdings Corporation
13.14.1 Company Overview
13.14.2 Financials
13.14.3 Product Portfolio
13.14.4 Recent Developments
13.15 Leica Biosystems
13.15.1 Company Overview
13.15.2 Financials
13.15.3 Product Portfolio
13.15.4 Recent Developments
14. GLOBAL LIVER CANCER DIAGNOSTICS MARKET COMMERCIAL FORECAST ANALYSIS
14.1 Imaging Diagnostics
14.2 Immunohistochemistry (IHC)-Based Diagnostics
14.3 Molecular Diagnostic Tests
14.4 Alpha-Fetoprotein (AFP) Tests
14.5 Liquid Biopsy Tests
14.6 Next-Generation Sequencing (NGS)-Based Tests
14.7 Companion Diagnostic Tests
15. INVESTMENT & FUNDING ANALYSIS
15.1 Venture Capital Trends
15.2 Government Funding
15.3 R&D Investments
16. FUTURE OUTLOOK
16.1 Key Growth Opportunities
16.2 Future Industry Trends
Navigate
Trusted by the world's leading organizations
